AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses ...

The company has out-licensed its Imsidolimab program, a treatment for generalized pustular psoriasis, to Vanda Pharmaceuticals, securing a $10 million upfront payment, an additional $5 million for ...

Experts say the research will divert funding to confirm what decades of research have already shown. HealthDay News — The U.S. Centers for Disease Control and Prevention (CDC) is preparing to study ...

Among the 63% of patients with generalized pustular psoriasis who experienced a flare, patients were more likely to be women, younger, and have more active disease. Generalized pustular psoriasis (GPP ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects ...

AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock? SAN ...

Swiss pharma giant Novartis came out on top last month in the mergers and acquisitions (M&As) space with its buyout of Massachusetts-based Anthos Therapeutics. The deal is worth up to $2.15 billion in ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports.

Hybrid closed-loop insulin delivery does not affect rate of severe hypoglycemia and increases rate of ketoacidosis. HealthDay News — For young people with type 1 diabetes, hybrid closed-loop ...